Related references
Note: Only part of the references are listed.Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions
Avi Ashkenazi
JOURNAL OF CLINICAL INVESTIGATION (2015)
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
M. H. Tuthill et al.
ONCOGENE (2015)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Getting TRAIL back on track for cancer therapy
J. Lemke et al.
CELL DEATH AND DIFFERENTIATION (2014)
Targeting cancer stem cells to suppress acquired chemotherapy resistance
S. J. Vidal et al.
ONCOGENE (2014)
Influence of the Implantation Site on the Sensitivity of Patient Pancreatic Tumor Xenografts to Apo2L/TRAIL Therapy
Rohit Sharma et al.
PANCREAS (2014)
TRAIL-Mediated Apoptosis in Breast Cancer Cells Cultured as 3D Spheroids
Siddarth Chandrasekaran et al.
PLOS ONE (2014)
GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft
Junsheng Fu et al.
CANCER LETTERS (2013)
Dormant Cancer Cells Contribute to Residual Disease in a Model of Reversible Pancreatic Cancer
Wan-chi Lin et al.
CANCER RESEARCH (2013)
Biology and Clinical Applications of Pancreatic Cancer Stem Cells
Ethan V. Abel et al.
GASTROENTEROLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity
Angelina I. Londono-Joshi et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Chemotherapy and Other Supportive Modalities in the Palliative Setting for Pancreatic Cancer
Kevin M. Sullivan et al.
CANCER JOURNAL (2012)
Heterogeneity and Targeting of Pancreatic Cancer Stem Cells
Vesselin R. Penchev et al.
CLINICAL CANCER RESEARCH (2012)
Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response
Zhigang Kang et al.
CLINICAL CANCER RESEARCH (2011)
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state
Christine L. Chaffer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
Andres Forero-Torres et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
Medulloblastoma-derived tumor stem-like cells acquired resistance to TRAIL-induced apoptosis and radiosensitivity
Cheng-Chia Yu et al.
CHILDS NERVOUS SYSTEM (2010)
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
D. Ross Camidge et al.
CLINICAL CANCER RESEARCH (2010)
A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model
N. V. Rajeshkumar et al.
MOLECULAR CANCER THERAPEUTICS (2010)
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
A. Singh et al.
ONCOGENE (2010)
Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation
David Capper et al.
ACTA NEUROPATHOLOGICA (2009)
Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer
Irene Zinonos et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
C. Adams et al.
CELL DEATH AND DIFFERENTIATION (2008)
Pancreatic cancer stem cells: Implications for the treatment of pancreatic cancer
Diane M. Simeone
CLINICAL CANCER RESEARCH (2008)
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
Xiaoxian Li et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
Avi Ashkenazi
NATURE REVIEWS DRUG DISCOVERY (2008)
Colorectal Cancer Stem Cells Are Enriched in Xenogeneic Tumors Following Chemotherapy
Scott J. Dylla et al.
PLOS ONE (2008)
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Jane E. Visvader et al.
NATURE REVIEWS CANCER (2008)
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy
Christine M. Fillmore et al.
BREAST CANCER RESEARCH (2008)
Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4
Robyn T. Sussman et al.
CANCER BIOLOGY & THERAPY (2007)
Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer
Patrick C. Hermann et al.
CELL STEM CELL (2007)
Phenotypic characterization of human colorectal cancer stem cells
Piero Dalerba et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Identification of pancreatic cancer stem cells
Chenwei Li et al.
CANCER RESEARCH (2007)
The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice
BL Hylander et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
Prospective identification of tumorigenic breast cancer cells
M Al-Hajj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
